Clinical aspects of gestational trophoblastic disease: a review based partly on 25-year experience of a statewide registry.
BACKGROUND
Gestational trophoblastic disease is a fascinating group of pregnancy disorders characterised by abnormal proliferation of trophoblast, ranging from benign to malignant. Because the disease is uncommon, there is a need to formulate management with the assistance of collective information.


METHODS
A review of available information from English written literature was undertaken, especially data reported by registries around the world (Charing Cross Hospital in England, the North-western University and the New England area in the USA as well as our own experience in Queensland, Australia). Where possible, collated data from relevant studies were analysed to answer some of the questions posed in clinical practice, with reference to metastatic disease to liver and brain, twinning of molar gestation and coexisting fetus, and placental-site tumour.


RESULTS
We found that molar gestation can be classified according to its clinical presentation which influences the time taken to reach human chorionic gonadotropin (HCG) 'negativity' and the risk of persisting disease. Categorisation of risk is the basis for choice of chemotherapy to achieve good outcomes. Metastases to liver and brain remain problems in management; the development of 'new' metastases during chemotherapy is a very poor prognostic factor. In the variant of twinning with molar gestation and coexisting fetus, it is important to elucidate the fetal karyotype in planning management: a 69XXX fetus is not salvageable but a normal 46XX or 46XY fetus faces the prospect of early preterm delivery. The placental-site tumour is very rare; localised disease is curable by surgery; chemotherapy is less effective in disseminated disease. From collated worldwide data, the recurrence rate after one mole is 1.3% and after two or more is 20%. Reproductive outcome in subsequent pregnancies, even after multidrug chemotherapy, is not different from the general population. Because of the increased risk long-term of second tumours after multidrug chemotherapy a closer surveillance of these patients is necessary.


CONCLUSIONS
In general, the disease in its persisting or malignant form is 'a cancer model par excellence' because of an identifiable precursor condition, a reliable HCG marker, and sensitivity of the disease to cytotoxic drugs. With current management, retention of fertility is possible and normal reproductive outcome assured.
Khoo
Soo-Keat
SK
Department of Obstetrics and Gynaecology, The University of Queensland and Director, Division of Gynaecology, Royal Women's Hospital, Brisbane, Australia. s.khoo@mailbox.uq.edu.au
D001932:Brain Neoplasms / Q000556:secondary / Q000628:therapy; D005260:Female; D031901:Gestational Trophoblastic Disease / Q000150:complications / Q000175:diagnosis* / Q000473:pathology / Q000628:therapy*; D006801:Humans; D006828:Hydatidiform Mole / Q000175:diagnosis; D002955:Leucovorin / Q000627:therapeutic use; D008113:Liver Neoplasms / Q000556:secondary / Q000628:therapy; D008727:Methotrexate / Q000627:therapeutic use; D016609:Neoplasms, Second Primary; D011247:Pregnancy; D011793:Queensland; D012008:Recurrence; D012042:Registries
D002955:Leucovorin; D008727:Methotrexate